IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer - Yahoo Finance

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  Yahoo Finance

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer.



Comments

Popular posts from this blog

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

How to perform chest auscultation and interpret the findings - Nursing Times

“National Day Awards 2019, Singapore News & Top Stories - The Straits Times” plus 1 more